Skip to main content
. 2013 Apr 5;288(20):14451–14462. doi: 10.1074/jbc.M113.460840

FIGURE 5.

FIGURE 5.

The C/EBPβ-HDAC1 complex down-regulates SIRT1 and PGC1α at later stages of liver cancer. A, top panel, location of three C/EBP sites within the PGC1α promoter. The bottom panel shows the nucleotide sequence of the PGC1α promoter and the C/EBP consensus sites. B, EMSA with the probe covering PGC1α site 3. The left panel shows the EMSA with overexpressed C/EBPα and C/EBPβ. The right panel shows the EMSA with liver nuclear extracts (NE). Positions of C/EBPα/β complexes, supershift (SS), and free probe are shown. C, the protein levels of SIRT1 and PGC1α are reduced at later stages of liver cancer. Western blotting was performed with the antibodies shown at the left. The bottom panel shows levels of SIRT1 and PGC1α as ratios to β-actin. D, levels SIRT1 and PGC1α mRNA are reduced at later stages of liver cancer. Quantitative RT-PCR was performed. Bar graphs show the results of analyses of three to four animals of each group. *, p < 0.05; **, p < 0.01, DEN treatment group versus control group. E, the SIRT1 and PGC1α promoters are repressed by C/EBPβ-HDAC1 complexes at later stages of liver cancer. A ChIP assay was performed with chromatin solutions as described in the legend to Fig. 4G. In, input; Ag, agarose beads; β, C/EBPβ.